scholarly journals Impact of statin therapy on plasma leptin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials

2016 ◽  
Vol 82 (6) ◽  
pp. 1674-1684 ◽  
Author(s):  
Amirhossein Sahebkar ◽  
Renato Giua ◽  
Claudio Pedone
PLoS ONE ◽  
2018 ◽  
Vol 13 (12) ◽  
pp. e0209486 ◽  
Author(s):  
Mohammed A. M. Farooqi ◽  
Nikita Malhotra ◽  
Som D. Mukherjee ◽  
Stephanie Sanger ◽  
Sukhbinder K. Dhesy-Thind ◽  
...  

2015 ◽  
Vol 243 (2) ◽  
pp. 579-588 ◽  
Author(s):  
Amirhossein Sahebkar ◽  
Luis E. Simental-Mendía ◽  
Gianna Ferretti ◽  
Tiziana Bacchetti ◽  
Jonathan Golledge

2018 ◽  
Vol 50 (02) ◽  
pp. 106-116
Author(s):  
Mohsen Mohammadi-Sartang ◽  
Zahra Sohrabi ◽  
Zahra Esmaeilinezhad ◽  
Seyed Aqaeinezhad R ◽  
Yahya Jalilpiran

AbstractThe results of human clinical trials examining the effects of conjugated linoleic acid (CLA) on leptin concentration are inconsistent. Our objective was to elucidate the role of conjugated linoleic acid supplementation on leptin through a systematic review and a meta-analysis of available randomized placebo-controlled trials (RCTs). We searched the PubMed, SCOPUS, and ISI web of science up to February2017, in English, to identify RCTs investigating the effect of CLA supplements on plasma leptin concentrations. Weighted mean differences (WMDs) and their respective 95% confidence intervals (CIs) were calculated to assess the efficacy of CLA on leptin concentration by using random effects. Statistical heterogeneity, study quality, meta-regression and publication bias were used based on standard methods. Nineteen RCTs (comprising 26 treatment arms) with 1045 subjects were included in this meta-analysis. Random-effect meta-analysis found a slight but not significant reduction in plasma leptin concentrations (WMD: –0.38 ng/ml, 95% CI: –1.08, 0.32, p=0.286); I2=53.24%, p=0.001), following CLA supplementation. The pooled effect size was robust and remained non-significant in the leave-one-out sensitivity analysis. Subgroup analysis based on BMI status showed that the CLA supplementation significantly reduces leptin when used for obese subjects (WMD: –1.47 ng/ml, 95% CI: –2.15, –0.79, p<0.001) and in the subset of trials lasting<24 weeks of duration (WMD: –0.76 ng/ml, 95% CI: –1.40, –0.12, p=0.019). CLA supplementation might moderately decrease circulatory leptin levels only among obese adults for shorter than 24 weeks. Additional high-quality studies are needed to replicate our results.


2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Alessandro Putzu ◽  
Carolina Maria Pinto Domingues de Carvalho e Silva ◽  
Juliano Pinheiro de Almeida ◽  
Alessandro Belletti ◽  
Tiziano Cassina ◽  
...  

2016 ◽  
Vol 103 ◽  
pp. 17-25 ◽  
Author(s):  
Amirhossein Sahebkar ◽  
Jana Rathouska ◽  
Luis E. Simental-Mendía ◽  
Petr Nachtigal

2015 ◽  
Vol 99 ◽  
pp. 329-336 ◽  
Author(s):  
Maciej Banach ◽  
Corina Serban ◽  
Sorin Ursoniu ◽  
Jacek Rysz ◽  
Paul Muntner ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document